We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Erythrocyte Complement Receptor 1 and Alzheimer Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01565434
First Posted: March 28, 2012
Last Update Posted: June 9, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
CHU de Reims
  Purpose
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Condition Intervention
Alzheimer Disease Other: CR1 impact

Study Type: Interventional
Study Design: Primary Purpose: Screening

Resource links provided by NLM:


Further study details as provided by CHU de Reims:

Enrollment: 200
Study Start Date: February 2012
Study Completion Date: April 2015
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

  • diseases modifying CR1 physiology
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565434


Locations
France
CHU de REIMS
Reims, France, 51092
Sponsors and Collaborators
CHU de Reims
  More Information

Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT01565434     History of Changes
Other Study ID Numbers: PA11014
First Submitted: March 26, 2012
First Posted: March 28, 2012
Last Update Posted: June 9, 2016
Last Verified: March 2012

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders